⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Novel Fusion GNAI2::BRAF as Driver for Pilocytic Astrocytoma: A Case Report (P4-5.009)

Maria Minor Gregory Chamberlin Justin Low Karra A. Jones Kevin Stevenson William Jeck Vanessa Smith

View at Publisher

Ask AI

Bookmark

Share

Abstract

To introduce a newly identified fusion, GNAI2::BRAF, as the oncogenic driver in a rare case of adult pilocytic astrocytoma

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Minor et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876780e5 https://doi.org/10.1212/wnl.0000000000205932

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Case Report: Molecular diagnostics and clinical courses of two adult spinal pilocytic astrocytoma long-term survivors with GTF2I::BRAF fusionCase Report · 2026
2Diagnostic challenges in an adult infratentorial pilocytic astrocytoma with a novel ZBTB20 BRAF fusionOriginal Research · 2026
3Coexistence of <scp>IDH1</scp> Mutation and <scp>KIAA1549</scp>::<scp>BRAF</scp> Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation2025
4A pilocytic astrocytoma with novel <i>ATG16L1::NTRK2</i> fusion responsive to larotrectinib: a case report with genomic and functional analysis2024 · 4 citations
5Integrating Molecular Analyses with the 2021 WHO Classification for a More Precise Diagnosis of Adult Pilocytic Astrocytomas2024

More related papers

Dabrafenib for Pilocytic Astrocytoma With <i>BRAF V599ins</i>2024
Abstract A032: Molecular insights into KIAA1549::BRAF fusion proteins: Implications for targeted therapy in pediatric low-grade gliomas2025
Spinal high-grade astrocytoma with piloid features arising in a patient with molecularly confirmed cerebellar pilocytic astrocytoma2026

More from Neurology

Blood-Based Biomarkers as Predictors of All-Cause DementiaFri,
Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,